CapsoVision, Inc. SEC Filings

CapsoVision, Inc. reporting person Rebecca Ann Petersen acquired 24,834 shares of common stock and holds stock options adjusted for a recent reverse split. The Form 4 shows a purchase of 24,834 shares at $0.3663 per share on 08/18/2025, resulting in 24,834 shares beneficially owned directly. The filing also reports two option grants (7,507 and 17,327 underlying shares) with an exercise price of $0.3663, exercisable through 10/31/2031 and 03/22/2032; the options’ share counts and exercise price reflect a 1-for-3.33 reverse stock split tied to the issuer’s IPO. One option is fully vested and the other is partially vested. The Form 4 was filed late due to an administrative error.

CapsoVision reported a transformative quarter highlighted by a completed IPO and continued operational challenges. The company completed an initial public offering in July 2025, selling 5,629,978 shares at $5.00 per share for gross proceeds of approximately $28.1 million and net proceeds of about $23.4 million. As of June 30, 2025, the company had approximately $1.1 million in cash and an accumulated deficit of $140.4 million. The financials for the six months ended June 30, 2025 show an operating loss of $10,033, a net loss of $10,000, and net cash used in operating activities of $9,512. Management disclosed substantial doubt about going concern.

The company executed a 1-for-3.33 reverse stock split effective July 2, 2025, converted outstanding preferred stock into common stock prior to the IPO, and increased authorized common shares to 300 million. Regulatory and product updates include a 510(k) filing for CapsoCam Colon in Q2 2025 targeting FDA clearance in early 2026 and a development agreement with Canon for CMOS sensors with up to $4.1 million in fees. Material weaknesses in internal controls were identified with remediation in progress.